Dual Bronchodilation With Qva149 Reduces COPD Exacerbations: The Spark Study

被引：0
|
作者：
Wedzicha, J. A. [1 ]
Decramer, M. [2 ]
Ficker, J. [3 ]
Taylor, A. Fowler [4 ]
D'Andrea, P. [4 ]
Arrasate, C. [4 ]
Berhane, I. [4 ]
Chen, H. [4 ]
Banerji, D. [4 ]
机构：
[1] UCL, London, England
[2] Katolik Univ Leuven, Leuven, Belgium
[3] Klinikum Nuernberg, Nurnberg, Germany
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2428
引用
收藏
页数：2
相关论文
共 50 条
  • [41] QVA149 ONCE DAILY PROVIDES SUPERIOR BRONCHODILATION VERSUS INDACATEROL, GLYCOPYRRONIUM, TIOTROPIUM AND PLACEBO: THE SHINE STUDY
    Barnes, N.
    Bateman, E.
    Gallagher, N.
    Green, Y.
    Horton, R.
    Henley, M.
    Banerji, D.
    THORAX, 2012, 67 : A147 - A148
  • [42] Comparison of COPD Exacerbations With Once-Daily QVA149 Versus Twice-Daily Salmeterol/Fluticasone Combination: The ILLUMINATE Study
    Bateman, Eric
    Vogelmeier, Claus
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [43] COMPARISON OF COPD EXACERBATIONS WITH ONCE-DAILY QVA149 VERSUS TWICE-DAILY SALMETEROL/FLUTICASONE COMBINATION: THE ILLUMINATE STUDY
    Vogelmeier, C.
    Bateman, E. D.
    Chen, H.
    Banerji, D.
    THORAX, 2013, 68 : A184 - A185
  • [44] Dual Bronchodilation With Once-Daily Qva149 Significantly Improves Lung Function Versus Single Bronchodilators And Salmeterol/fluticasone
    Bateman, E. D.
    Ferguson, G. T.
    Welte, T.
    D'Andrea, P.
    Alagappan, V.
    Chen, H.
    Green, Y.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [45] Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
    Horita, Nobuyuki
    Kaneko, Takeshi
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 813 - 822
  • [46] Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study
    Wedzicha, Jadwiga A.
    Decramer, Marc
    Ficker, Joachim H.
    Niewoehner, Dennis E.
    Sandstrom, Thomas
    Taylor, Angel Fowler
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    LANCET RESPIRATORY MEDICINE, 2013, 1 (03): : 199 - 209
  • [47] DUAL BRONCHODILATION WITH QVA149 IN PATIENTS WITH SEVERE AND VERY SEVERE COPD - ARE THERE INCREMENTAL BENEFITS FOR PORTUGUESE PATIENTS AND FOR THE PORTUGUESE NHS WHEN COMPARED WITH CURRENT TREATMENT OPTIONS IN PORTUGAL?
    Carrasco, J.
    Viriato, D.
    Cardoso, I
    VALUE IN HEALTH, 2015, 18 (07) : A500 - A500
  • [48] Dual Bronchodilation With QVA149 Improves Dyspnea in Patients With Moderate-to-Severe COPD: Pooled Analysis From the FLIGHT1 and FLIGHT2 Studies
    Mahler, Donald
    Larbig, Michael
    Patalano, Francesco
    Maitra, Samopriyo
    Banerji, Donald
    CHEST, 2015, 148 (04)
  • [49] Once-Daily Qva149 Improves Symptom Scores In Patients With COPD
    Welte, T.
    Dahl, R.
    Chen, H.
    Gallagher, N.
    D'Andrea, P.
    Alagappan, V.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [50] QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
    van Noord, Jan A.
    Buhl, Roland
    LaForce, Craig
    Martin, Carmen
    Jones, Francis
    Dolker, Michael
    Overend, Tim
    THORAX, 2010, 65 (12) : 1086 - 1091
12345